证券之星消息，12月9日发布《富达悦享红利优选混合型证券投资基金 2025年度第二次分红公告》。本 次分红为2025年度第二次分红。公告显示，本次分红的收益分配基准日为12月12日，详细分红方案如 下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 分级基金筒称 | 代码 | 墓准日基金净值 分红方案 | | | | --- | --- | --- | --- | --- | | | | (元) | | (元/10份) | | 富达悦享红利优选混合A 020493 | | | 1.19 | 0.28 | | 富达悦享红利优选混合C 020494 | | | 1.17 | 0.28 | 本次分红对象为权益登记日在本基金注册登记机构登记在册的本基金全体基金份额持有人。，权益登记 日为12月11日，现金红利发放日为12月15日。对于选择红利再投资方式的投资者，将以2025年12月11日 的基金份额净值为计算基准确定再投资份额，本基金注册登记机构将于2025年12月12日对红利再投资的 基金份额进行确认，2025年12月15日起可以查 ...

Group 1 - China Shenhua's stock price increased by 0.52% to 40.86 CNY per share, with a trading volume of 1.545 billion CNY and a market capitalization of 811.828 billion CNY as of October 15 [1] - The stock has risen for six consecutive days, with a cumulative increase of 6.54% during this period [1] - The company's main business segments include coal (75.23%), power generation (29.35%), rail transport (15.52%), port operations (2.51%), coal chemical (2.11%), and shipping (1.19%) [1] Group 2 - Fidelity's fund, "Fidelity Enjoys Dividend Preferred Mixed A" (020493), holds 226,000 shares of China Shenhua, representing 4.14% of the fund's net value, making it the ninth-largest holding [2] - The fund has realized a floating profit of approximately 47,500 CNY today and 567,300 CNY during the six-day increase [2] - The fund has a total asset size of 49.288 million CNY and has achieved a year-to-date return of 24.58% [2] Group 3 - The fund manager, Nie Yixiang, has been in position for 8 years and 76 days, with a total asset size of 30.7 million CNY and a best return of 135.58% during his tenure [3] - Co-manager Zhou Wenqun has been in position for 2 years and 175 days, managing assets of 48.2 million CNY with a best return of 39.09% [3]

Core Viewpoint - The AI Fund Fidelity Enjoy Dividend Preferred Mixed A (020493) reported a profit of 7.5547 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0873 yuan, and a net asset value growth rate of 10.19% during the same period [2]. Fund Performance - As of September 3, the fund's net asset value growth rate over the past three months was 16.30%, ranking 384 out of 607 comparable funds; over the past six months, it was 22.44%, ranking 237 out of 607; and over the past year, it was 25.69%, ranking 500 out of 604 [4]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 7.05 times, compared to the industry average of 33.74 times; the weighted average price-to-book (P/B) ratio was about 0.5 times, against an industry average of 2.47 times; and the weighted average price-to-sales (P/S) ratio was around 0.98 times, while the industry average was 2.07 times, indicating that all three valuation metrics are below the industry average [9]. Growth Metrics - For the first half of 2025, the weighted average year-on-year revenue growth rate (TTM) of the stocks held by the fund was 0.05%, and the weighted average net profit growth rate (TTM) was 0.03%, with a weighted annualized return on equity of 0.07% [15]. Fund Size and Shareholder Composition - As of June 30, 2025, the fund's total size was 49.2887 million yuan, with 839 holders collectively owning 46.5021 million shares. Management employees held 531,100 shares, accounting for 1.14%, while individual investors held 100% of the shares [31][34]. Trading Activity - The fund's turnover rate over the last six months was approximately 140.96%, which is consistently lower than the industry average [37].

Core Insights - Foreign public funds have shown strong performance in Q2, with a focus on structural opportunities in the Chinese market, particularly in artificial intelligence, innovative pharmaceuticals, and high-dividend assets [1][2][3] Group 1: Fund Performance - Several foreign public equity products achieved notable returns in Q2, with the Robeco China Healthcare Equity Fund leading at a 28.51% increase in net value [1] - BlackRock's Advanced Manufacturing Fund and Fidelity's Dividend Growth Fund reported net value increases of 21.83% and 13.64%, respectively [1] Group 2: Investment Strategies - Robeco emphasized a multi-dimensional evaluation of companies in the innovative sector, focusing on quality, talent, R&D investment, and clinical data to select high-potential firms [1] - BlackRock's fund manager highlighted a strategic focus on artificial intelligence and technology sectors, achieving significant excess returns [2] - Fidelity's managers noted strong performance in traditional dividend sectors, attracting risk-averse capital due to low valuations and high dividend certainty [2] Group 3: Future Outlook - Fund managers expressed optimism about the attractiveness of A-share valuations, supported by policy backing and positive industry trends, indicating ongoing structural opportunities [2] - Future investment will continue to prioritize high-quality technology assets and sectors with concentrated distribution, such as TMT, machinery, pharmaceuticals, and chemicals [3] - The Chinese pharmaceutical industry is expected to enhance its global competitiveness, with a clear trend towards international expansion in innovative drugs and medical devices [3]